



## Review

## Improving completion rates of patient-reported outcome measures in cancer clinical trials: Scoping review investigating the implications for trial designs



Lotte van der Weijst<sup>a,\*</sup>, Abigirl Machingura<sup>a</sup>, Ahu Alanya<sup>a</sup>, Emma Lidington<sup>b</sup>, Galina Velikova<sup>c,d</sup>, Hans-Henning Flechtner<sup>e</sup>, Heike Schmidt<sup>f</sup>, Jens Lehmann<sup>g</sup>, John K. Ramage<sup>h</sup>, Jolie Ringash<sup>i</sup>, Katarzyna Wac<sup>j</sup>, Kathy Oliver<sup>k</sup>, Katherine J. Taylor<sup>l,m</sup>, Lisa Wintner<sup>g</sup>, Lúcia P.C. Senna<sup>a</sup>, Michael Koller<sup>n</sup>, Olga Husson<sup>o,p</sup>, Renée Bultijnck<sup>q</sup>, Roger Wilson<sup>r</sup>, Susanne Singer<sup>l,m</sup>, Vesna Bjelic-Radisic<sup>s</sup>, Winette T.A. van der Graaf<sup>o,t</sup>, Madeline Pe<sup>a</sup>, on behalf of the EORTC Quality of Life Group

<sup>a</sup> Quality of Life Department, EORTC, Brussels, Belgium

<sup>b</sup> Cancer Prevention Trials Unit, Queen Mary University of London, London, United Kingdom

<sup>c</sup> Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK

<sup>d</sup> Leeds Teaching Hospitals NHS Trust, Leeds, UK

<sup>e</sup> Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Magdeburg, Magdeburg, Germany

<sup>f</sup> Department for Radiation Medicine and Institute of Health and Nursing Science Medical Faculty, Martin Luther University Halle-Wittenberg, Halle, Germany

<sup>g</sup> University Hospital of Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria

<sup>h</sup> Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom

<sup>i</sup> Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

<sup>j</sup> Quality of Life Lab, Center for Informatics, University of Geneva, Switzerland

<sup>k</sup> International Brain Tumour Alliance, Surrey, United Kingdom

<sup>l</sup> Institute of Medical Biostatistics Epidemiology and Informatics (IMBEI), University Medical Centre Mainz, Mainz, Germany

<sup>m</sup> University Cancer Centre, Mainz, Germany

<sup>n</sup> Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany

<sup>o</sup> Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands

<sup>p</sup> Department of Surgical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands

<sup>q</sup> Department of Human Structure and Repair, Ghent University, Ghent, Belgium

<sup>r</sup> Cancer Research Advocates Forum UK, Sarcoma Patient Advocacy Global Network (SPAGN), Shropshire UK

<sup>s</sup> Breast Unit, University Hospital Helios, University Witten Herdecke, Wuppertal, Germany

<sup>t</sup> Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, the Netherlands

## ARTICLE INFO

## Keywords:

Patient reported outcome measures

Review

Neoplasms

Completion rates

Trial conduct

Missing data

## ABSTRACT

**Background:** Patient-reported outcomes (PROs) play a crucial role in cancer clinical trials. Despite the availability of validated PRO measures (PROMs), challenges related to low completion rates and missing data remain, potentially affecting the trial results' validity.

This review explored strategies to improve and maintain high PROM completion rates in cancer clinical trials.

**Methodology:** A scoping review was performed across Medline, Embase and Scopus and regulatory guidelines. Key recommendations were synthesized into categories such as stakeholder involvement, study design, PRO assessment, mode of assessment, participant support, and monitoring.

**Results:** The review identified 114 recommendations from 18 papers (16 peer-reviewed articles and 2 policy documents). The recommendations included integrating comprehensive PRO information into the study protocol, enhancing patient involvement during the protocol development phase and in education, and collecting relevant PRO data at clinically meaningful time points. Electronic data collection, effective monitoring systems, and sufficient time, capacity, workforce and financial resources were highlighted.

\* Corresponding author.

E-mail address: [lotte.vanderweijst@eortc.org](mailto:lotte.vanderweijst@eortc.org) (L. van der Weijst).

<https://doi.org/10.1016/j.ejca.2024.114313>

Received 26 July 2024; Accepted 2 September 2024

Available online 18 September 2024

0959-8049/© 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

*Discussion:* Further research needs to evaluate the effectiveness of these strategies in various context and to tailor these recommendations into practical and effective strategies. This will enhance PRO completion rates and patient-centred care. However, obstacles such as patient burden, low health literacy, and conflicting recommendations may present challenges in application.

## 1. Introduction

The value of assessing patient-reported outcomes (PROs) in cancer clinical trials is increasingly recognized by patients, policymakers and regulatory agencies [1]. PRO measures (PROMs) enable patients to report their well-being, functioning, disease-related symptoms, treatment-induced toxicities and other issues related to health-related quality of life (HRQoL).

The implementation of PROMs in clinical trials needs improvement to ensure relevant and accurate data [2]. High-quality PRO data collection before analysis is crucial, yet low completion rates and missing data remain challenges. [1,3].

A systematic analysis revealed 95 % of trials report missing PRO data, with a median of 9 %, ranging from 0–70 %, threatening internal validity and generalizability [4,5].

While statistical handling of missing PRO data is well-researched, a preferred strategy is to prevent missing data by improving completion rates [1,6]. Completion rate refers to the ratio of PRO assessments received versus expected within a timeframe [1]. Various factors influence PROM completion rates, including trial design, logistics, administration, and patient-related issues. Implementing strategies in these areas can maintain and improve PRO completion rates [7].

This scoping review aims to provide a synopsis of published strategies to improve and maintain high PROM completion rates in cancer clinical trials, focusing on mapping evidence rather than conducting a critical appraisal of individual studies."

## 2. Methodology

### 2.1. Literature search

A literature search on strategies to improve PROM completion rates in cancer clinical trials was conducted in Medline, Embase and Scopus. The full search strategies can be found in appendix 1. The last search was performed on January 2nd, 2024. References of eligible articles were screened. Policy documents and guidelines from leading regulatory and cancer organizations were consulted. Reporting is based on the PRISMA extension for scoping reviews [8].

### 2.2. Study selection

All journal articles published in English between January 2012 and December 2023 with guidance on improving PROM completion rates for adult cancer patients in clinical trial settings were included.

Policy papers with strategies to enhance completion rates of PRO data for cancer patients in clinical trial settings were also included. Cancer survivorship research referring to studies on the long-term effects of cancer and its treatment were excluded. Conference presentations, study protocols, and publications not relevant to clinical trial settings, without full-text availability, or written in a language other than English were excluded.

### 2.3. Study selection and data extraction

Study selection involved screening titles and abstracts by a single reviewer, with a second reviewer screening 10 % for reliability and accuracy of the findings. Given the absence of disagreements between the first and second reviewer, it was concluded that single-reviewer screening was appropriate for ensuring consistence in abstract

selection. Full-text papers were assessed by two reviewers. General study characteristics and recommendations were extracted using a pilot-tested form and categorized per the structure of the Standard Protocol Items: Recommendations for Interventional Trials – PRO (SPIRIT-PRO) statement [9].

## 3. Results

A total of 2963 abstracts were identified and screened, and 65 papers underwent full-text review. Altogether, 16 peer-reviewed papers and 2 policy papers were included in this review. Fig. 1 provides a summary of the review process.

### 3.1. General description of papers included in the literature review

Eighteen papers in total were included in this review, categorised as clinical trials (n = 8; 44 %), reviews (n = 5, 28 %), guidelines (n = 2; 11 %) meta-analyses (n = 1; 6 %), qualitative study (n = 1; 6 %) and an editorial (n = 1; 6 %). Table 1. provides details of the included papers. Although only 5 (28 %) of the papers provided a definition for completion rate (see appendix for definitions of completion rate), the majority (n = 10; 56 %) provided reasons for low completion rates. These reasons included process-based [10] and administrative reasons [11–14] staff's lack of perceived value of PROMs and lack of adequate time in personnel schedule [15,16] patients' attitude [10], patients' well-being including being too unwell or tired [10,12,17] patient refusal, missed appointments [11] or patients forgetting to complete and return the PROM [13,17,18] as well as the lack of feedback regarding the PROM outcome [16]. In total, 114 different recommendations to increase completion rates have been identified. The most frequently cited recommendations included the following: using electronic PROMs (n = 7), educating participants about PROs at the study start (n = 5), collecting clinically relevant PRO data (n = 5), providing training to site personnel (n = 4), sending participant reminders (n = 4) and collecting reasons for missing data and about non-responders (n = 4). The recommendations are summarised into 8 categories in Table 2. A summary of the recommendations can be found below.

### 3.2. Identified recommendations

#### 3.2.1. Stakeholders involved and study design

A committed, collaborative and trained team and site coordinator is essential throughout the study design [13,15,19–21]. Patient involvement remains critical during protocol development [19].

The study protocol should include comprehensive PRO information, such as the PRO specific endpoint, rationale for the PRO assessment, patient population, handling of missing data and data collection time points [15,20]. These time points should be practically feasible, clinically meaningful and aligned with patients' visits to the clinic and scheduled prior to medical consultations or procedures [19,22].

It is recommended to make staff require to try to obtain PRO data in study and include PRO data as an eligibility criterion as it shows the importance of PRO data collection [19,21]. PROMs should also be introduced by a trusted clinician at an appropriate time [10].

In one study, the importance of a wide enough window for back-up PRO data collection was identified [23]. The completion time of PROMs and therefore the length of the survey should be limited to avoid additional patient burden [23]. The location of PRO data collection should be private and flexible, allowing patients to complete PROMs remotely

and in the clinic [17,21,24]. Additionally, it is recommended to conduct a pilot study to assess the feasibility of collecting PROM data [21].

### 3.2.2. PRO assessment, PROM characteristics and mode of assessment

Careful selection of PROMs, considering the content's clinical relevance, characteristics of the target population and potential patient burden, is important [19]. The format of the PROM should be clear and professional [24].

A multi-model data collection approach, including electronic and paper-based PROM options, should be offered [25], with preference given to electronic data collection [18,22,26].

Electronic PROMs (ePROMs) should allow for automated data collection, reminders and feedback, real-time compliance monitoring, and should have an intuitive interface, include boxes for missing items and options for patients with tactile, vision or hearing disabilities [23]. The use of ePROMs should be easy without difficult passwords and software [10–13,16,18,19,23,25–27]. Display PRO results in a user-friendly manner for clinicians and patients is also deemed useful [10].

### 3.2.3. Participant support and education

Education of patients on the importance of PRO data and how to complete a PROM as well as automated feedback to the patient based on their outcomes also contributes to higher completion rates [13,19–23]. Providing instructions to guide patients in the completion of PROMs, identifying those who need help, offering assistance, and providing tablets with data allowance for remote completion of ePROMs are essential [10]. Encouraging patients to complete PROMs, for example with non-financial incentives, is recommended [13,17].

### 3.2.4. Monitoring and resources

Central and site monitoring are important, and awareness of compliance issues should be raised during site committee meetings [10, 11,13,19–21,23]. Reminders for PROM completion should be implemented, with personnel contacting participants if no response is received after automatic reminders are sent [23]. However, particularly patients with advanced cancer may prefer not to receive reminders as this reminds them of their poor health [16]. Data should be collected on reasons for missing PRO data as this may provide insight on completion issues and is valuable for statistical modelling of missingness [10,11,19, 23].

PRO data should be handled with the same importance as other clinical data, and sufficient resources should be allocated to support both patients and staff [21]. It is important to allocate time, capacity, workforce and financial resources to handle issues occurring outside of

the clinical appointments, especially if data is electronically collected at home [10]. Additionally, PROs could be incorporated into clinical systems to ensure efficient use by health care staff [10].

## 4. Discussion

This scoping review highlights strategies to improve PROM completion rates in clinical trials and underscores the importance of considering clinical relevance and practical feasibility.

A multidisciplinary team including patients involved in protocol development, PROM selection and study implementation is vital [13,15, 19,20].

Supporting and assisting both patients and study staff and highlighting to them the importance of PRO data collection, and providing updates on completion rates and interim results, are important during the study. Central and site-specific monitoring system coupled with adequate resources is imperative. Patient, staff and institute burden should be consistently considered in all phases of the study. While our data is applicable to the cancer clinical trial setting; it aligns with broader literature reviews [6,28,29]. These reviews stress the crucial role of staff commitment and advocate for meticulous planning and ongoing monitoring of activities. They emphasize the importance of motivating patients to complete PROMs, while considering resource and patient burden and providing technology that integrates PRO data into existing clinical workflows. Patient engagement and sharing information about the study remains essential throughout the study [6,28].

### 4.1. Barriers in improving completion rates in cancer clinical trials

The involvement of patients is not routinely implemented and varies greatly in current cancer clinical trials [30–32]. To include the patient's perspective and improve PRO completion rates, their involvement in PROM implementation in clinical trials is essential [6,28,31].

Patients and patient advocates offer invaluable insight regarding PROMs, appropriate recall interval, assessment time points, patient burden and strategies for engaging them [28]. Moreover, patient advocacy organisations play an important role in promoting the acceptance of PROMs, support patient education on the how to complete them and have the capacity to disseminate information and raise awareness about the importance of PROMs and PRO completion rates globally, given their representation of vast numbers of patients and caregivers worldwide.

Successful patient involvement in PRO implementation in clinical trials requires resources, education and dedicated commitment of both patients and involved staff. The challenges associated with involving




Fig. 1. Flow chart describing the selection of eligible papers.

**Table 1**  
Details of included papers.

Reference	Type of paper	In case of clinical study, type of study	Main objective of paper	Type of cancer	PROM	Frequency of PRO assessment	Completion rate (%)	Reasons no completion
Appleyard (2021) [11]	Clinical study	Feasibility study	To explore the feasibility of collecting ePROs in older prostate cancer patients with different digital experience.	Prostate cancer	EQ-5D; EORTC QLQ-C30; PR25	Baseline, 1, 2 and 3 months	100 (n = 40) (baseline, 88 (n = 35) (3 months)	Lost to follow-up
Atherton (2016) [12]	Meta-analysis	N/A	To determine the extent of, and characteristics associated with, missing PROs.	Multiple cancer types	N/A			
Basch (2019) [13]	Editorial	N/A	To review strategies to optimize PROMs completion in clinical trials.	Any cancer	N/A			
EMA (2014) [14]	Guideline	N/A	To provide guidance on the use of PROMs in oncology studies.	Any cancer	N/A			
EORTC (2002) [15]	Guideline	N/A	To provide guidance for assessing QoL in EORTC trials.	Any cancer	N/A			
Flannery (2022) [16]	Clinical study	RCT	To determine whether and the type of assistance with PRO completion older advanced cancer adults (70 +) need.	Multiple cancer types	OARS, Fall history, GAD-7, GDS, Health Care Climate Questionnaire; Press-Ganey Patient Satisfaction Survey; FACT-G, MDASI, The Distress Thermometer; INQ-R; RDED, PEACE, PEPPi scale, Control Preferences Scale; MUIS-Complexity Subscale.	Baseline, 6 weeks, 3 months, 6 months	Not reported	Mainly due to death or hospitalization/hospice
Friis (2020) [17]	Clinical study	Feasibility study	To design an ePROM for symptom monitoring and to evaluate the feasibility, usability and acceptability in metastatic lung cancer patients.	Lung cancer	EORTC QLQ-C30, LC13	Weekly for 4 weeks	100, 100, 94, 78	Not reported
Giordano (2020) [18]	Review	N/A	To discuss challenges of implementing ePROMs.	Not specified	N/A			
Hoque (2019) [19]	Clinical study	RCT	To compare three different methods of PROM data collection.	Prostate cancer	EPIC-26	1 time	98	Not reported
Kennedy (2021) [20]	Clinical study	Feasibility study	To explore compliance and acceptability of an ePROM on self-reported AEs and HRQoL.	Multiple cancer types	EORTC QLQ-C30; PRO-CTCAE	PRO-CTCAE: weekly, QLQ-C30: every 4 weeks for 12 weeks	QLQ-C30: 96.0, 88.5, 84.5, 79.1	Death and withdrawal (including time required to participate, being unwell, stopped treatment, computer problems)
King-Kallimani (2021) [21]	Review	N/A	To assess PROs after treatment discontinuation collected in commercial clinical trials.	Multiple cancer types	N/A			
Lidington (2022) [22]	Review	N/A	To examine the protocol content, data completeness and publication of PROs from interventional trials and explore factors associated with data missingness and PRO publication.	Multiple cancer types	N/A			
Movsas (2014) [23]	Clinical study	RCT	To test the feasibility of an electronic web-based system to improve compliance.	Prostate cancer	EPIC	Baseline, 6 and 12 months	98, 96, 82	Patient refusal, patient could not be contacted or unknown

(continued on next page)

Table 1 (continued)

Reference	Type of paper	In case of clinical study, type of study	Main objective of paper	Type of cancer	PROM	Frequency of PRO assessment	Completion rate (%)	Reasons no completion
Pugh (2021) [24]	Review	N/A	To evaluate the effectiveness of email reminders and notifications on PROM submission timeliness and compliance.	Breast & prostate	N/A			
Romano (2022) [25]	Qualitative study	N/A	To characterize the experience of metastatic breast cancer patients with PROMs in a clinical trial setting to determine the importance, relevance, barriers, and facilitators for completion.	Breast	N/A			
Teixeira (2022) [26]	Review	N/A	To analyse PROs used for regulatory approval of oncology drugs within the EU.	Multiple cancer types	N/A			
Tran (2020) [27]	Clinical study	Pilot study	To explore the feasibility and acceptability of collecting ePROs using validated HRQoL PROMs for prostate cancer.	Prostate cancer	EPIC-26, EPIC-CP, FAPSI-8	Weekly for 12 weeks	Not reported	Not reported
Zivanovic (2020) [28]	Clinical study	Pilot study	To evaluate the feasibility of an electronic symptom-tracking platform for patients recovering from ambulatory surgery.	Gynaecologic cancer	PRO-CTCAE	Daily for 6 days	10, 13, 9, 11, 13, 41	Too tired, not remembering, or having technical difficulties with the computer

Abbreviations: AE, adverse event; EORTC, European Organisation for Research and Treatment of Cancer; EPIC-26, Expanded Prostate Cancer Index; EPIC-CP, Expanded Prostate Cancer Index Composite for Clinical Practice EQ-5D, EuroQoL 5 Dimension; ePRO, electronic patient-reported outcome; ePROM, electronic patient-reported outcome measures; EU, European Union; FACT-G, Functional Assessment of Cancer Therapy – General; FAPSI-8 Functional Assessment of Cancer Therapy Advanced Prostate Symptom Index; FDA, Food and Drug Administration; GDS, Geriatric Depression Scale; HRQoL, health-related quality of life; INQ-R, Interpersonal Needs Questionnaire-Revised; LC, lung cancer; MUIS, measurement of uncertainty in illness; MDASI, MD Anderson Symptom Inventory; N/A, not applicable; OARS, Older American Resources and Services; PEACE, Peace, Equanimity, and Acceptance in the Cancer Experience; PEPI, Perceived Efficacy in Patient-Physician Interactions; PRO, patient-reported outcome; PRO-CTCAE, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events; PROM, patient-reported outcome measure; QLQ-C30 Quality of Life Questionnaire - Core; PR, prostate cancer; RCT, randomized-controlled trial; RDED, Reluctance to Disclose Emotional Distress; QoL, quality of life

patients in clinical trial design have been extensively documented [32]. Practical guidance exists on incorporating patients' perspectives into the design of clinical trials, but no specific guidelines are currently available on the PRO part of the study [33]. This calls for more research into the engagement of patients and patient advocacy organisations in protocol development for clinical trials with PRO endpoints. This research is crucial, as their active participation aims to enhance both the study's quality and representation of patients' perspective.

A major barrier to the successful implementation of PROMs is the requirement of additional human and financial resources [34]. The recommendations in the literature review include selecting trained staff to coordinate and monitor PRO activities and appointing site staff responsible for PRO data collection and patient engagement. However, this can result in an increased workload for the staff, which is particularly challenging due to the difficulty in finding qualified healthcare staff in the current era. Hence, efficient integration of PRO data collection into the health care professionals' workflow is essential [35]. Supporting this integration requires infrastructure for data management, education materials and monitoring systems [34,35].

Despite the numerous recommendations found in our review, none directly addressed the challenges of language barriers, literacy and health literacy or digital literacy in (highly relevant for ePRO). However, a previous study showed a trend between lower PRO completion rates and patients with a primary language different from the local language [36].

Furthermore, approximately 20 % of the European population is functionally illiterate [37]. This refers to the lack of essential reading and writing skills required to function in society, presenting a significant challenge to completing PROMs. Patients with low literacy levels and health care staff have reported feeling embarrassment when faced with patients' literacy challenges. These patients may lack confidence in completing PROMs and may provide excuses to avoid completing them. Health professionals, on the other hand, may be hesitant to address suspected low literacy out of concern that labelling patients as such could discourage them from returning to the clinic.

To address these challenges, it is important to ensure that PROMs and associated PRO training materials are designed to be comprehensible to patients with varying literacy and educational backgrounds. Additionally, providing patients with PROMs in their native language, offering assistance and performing relevant readability assessments can further improve the PRO completion rates. All of these recommendations shall be amplified by an intuitive interface and adequate interaction design, in case of ePRO modality for the PRO collection, especially if conducted in the daily life environments of the patients.

Our review identified numerous recommendations for improving completion rates in cancer clinical trials. However, it remains unclear which of these recommendations are both practical and significant in enhancing completion rates. Furthermore, implementing a total of 114 recommendations presents a practical obstacle, particularly as some recommendations seem to conflict with each other. For example,

**Table 2**  
Overview of trial design implications to improve completion of PRO assessment.

Category	Sub-category	Specific recommendations*	
<u>Stakeholders involved</u>	Patient involvement	<b>Involve patients in PRO study design</b> Involve patients in PROM selection, study design (e.g., PRO frequency, assessment modalities), and overall study feasibility assessment	
	Staff involvement	<b>Commitment from all staff, including physicians</b> Collaboration between study coordinator, data centre and individual organisation Regular contact between data manager/nurse and the study investigator The study coordinators need to understand the value and rationale of PROMs and need to use this data to motivate the study investigators Select staff to coordinate and monitor PRO activities throughout the study <b>Appoint a PRO trained and qualified person responsible for PRO data collection in each study site</b> Committed to the study Interpersonal skills, basic technical skills if ePRO are included	
	Characteristics of site coordinator Train/support staff	<b>Offer training at start and throughout the study to site staff, site coordinators and clinical investigators</b> Train staff on purpose and importance of PRO assessments Educate staff on the protocol conduct Ensure staff is familiar with system from patient perspective to trouble shoot issues related to ePRO Offer support to sites/staff (e.g., psychological support, bereavement counselling) Educate sponsors National training courses in data management could include general issues around PRO data collection Publish and promote PRO data if the data has contributed to the scientific validity of the study	
<u>Study design</u>	Protocol development	<b>Comprehensive PRO information, including PRO timing, PRO assessment modalities in study protocols</b> Include/plan PRO aspects of the study carefully (e.g., PRO frequency, assessment modalities) Protocol adherence to SPIRIT-PRO guideline Use behaviour theory-informed motivational information in the protocol Specify the rationale for PRO assessment Well-defined and adequate population described in study protocol Specify how missing data will be handled Develop protocol guidance for investigators Publish guidelines providing recommendations and best practices on PRO strategy	
	Objective	Define endpoints/hypotheses and ensure PRO endpoint is scientifically compelling Defined research objective for follow-up PRO data Make PRO a co-primary endpoint	
	Eligibility criteria	<b>Make baseline PROM an eligibility criterion when ethically justifiable and practically feasible</b> PRO data collection should be mandatory and integral part of the study	
	Pilot study	Implement local pilot study prior to the start of the main study, followed by a debriefing meeting	
	<u>PRO assessment</u>	Time point selection	<b>Specify the required PRO assessment time points</b> Select clinically meaningful time points, while considering the PRO recall period Timepoints when expected high levels of completion by the individual patient Consider patient burden In case of event-driven PRO assessment, only preform in a subsample rather than subjecting the entire sample
		Time window	A wide enough window for backup data collection
		Completion time	Limit estimated completion time of baseline PRO assessments to 20 minutes and 10-15 minutes completion for subsequent assessments
Time of completion		Align PRO assessments to clinic visits to capture while the patient visits the clinic PROMs should be administered at the beginning of a clinic visit prior to medical interviews or procedures	
Treatment cessation Introduction of PROM		Specify procedures for contacting participants for PRO assessment after treatment cessation Introduced PROM by trusted clinician Appropriate timing of PROM introduction	
Location of assessment	<b>Combine remote/home-based completions by using ePROMS</b> While in clinic, provide a private and comfortable environment for completing PROM		
<u>Characteristics of PROM</u>	PROM selection	Select the most appropriate instrument <b>Collect clinically relevant PRO data</b> <b>Clear/simple content and instructions of questionnaires</b> Allow patients to skip irrelevant items <b>Minimise patient burden</b> Address feedback from patients on burdensome items or format during PROM validation process	
	Length	<b>Should be brief (no more than 40–50 items if infrequently administered; no more than 10–20 questions if frequently administered)</b>	
	Format	User-focused PRO design Clear/simple format Large/clear font	
	<u>Mode of assessment</u>	Choice of MOA	<b>Multi-modal data collection approach (including ePROM and paper-based PROMs)</b> <b>ePROM is encouraged</b>
ePROM features		Use of automated electronic data collection Keep it simple, without difficult passwords, soft/hardware <b>Allows real-time compliance monitoring</b> <b>Allow participants to complete on their preferred electronic device</b> Provision of login details on paper and via e-mail Intuitive interface, Should offer options to participants with tactile, vision, or hearing impairments (e.g., choice of web, handheld, or automated telephone system) Adjustable font size Read aloud options Automatic completion confirmation	

(continued on next page)



Table 2 (continued)

Category	Sub-category	Specific recommendations*		
<u>Participant support and education</u>	Support	<b>E-mail PRO assessment reminders to participants</b> Importance of real-time feedback to users so that they can be confident that their responses have been recorded Potential for family and friends to facilitate digital access Provide tailored advice to patients based on their responses User-friendly presentation of longitudinal results for clinician and patient Dialogue boxes for missed items		
		Instructions to give to participants must be specified in PRO administration guidance Available staff to give verbal explanation during the first time the patient is asked to complete PROM Provide a verbal clear explanation on the reasons for collecting. This information should be supported by a written information sheet Inform patients what will happen to their complete PROMs Provide information on when the PROMs are due User guide on paper and electronically		
		<b>Prospective identification of patients who are less able to complete</b> <b>Offer assistance to participants who need it</b>		
		Provide encouragement to participants when completing PROs Showing appreciation once the questionnaire is completed and expressing an interest in any concerns the patient may raise Provide a tablet/data allowance		
		<b>Feedback</b> Opportunities for the patient to make inquiries to the medical staff Reference to questionnaire responses by clinicians Feedback to the user regarding their previous answers to the questionnaire Feedback based on the patient-reported symptoms to act or not Predictive information encourages engagement and healthy behaviour change		
		<b>Education</b> <b>Educate participants about PROs at the onset of study</b>		
		<b>Incentives</b> Providing participants, a summary of trial results, include potential publication/ reports to study participants Offer participants non-financial incentives		
		<b>Proxy</b> <b>Proxy completion can be considered by a caregiver or family member if data is missing (for example, a brain tumour patient may have cognitive impairments which would make it difficult for the patient to complete the questionnaire).</b>		
		<u>Monitoring</u>	Central monitoring	<b>Central office monitors compliance</b> <b>Efficient compliance management tools such as online reports and email notifications</b> Staff should be contacted, engaged, and be accountable when a participant at their site is not compliant with a PRO questionnaire <b>Real-time monitoring of PRO completion. This can then prompt an intervention if PRO assessments are missed</b> Rapid follow up for missing data may be required due to the recall period <b>Raise awareness of compliance issues through presentations, newsletter articles and leading discussions at disease site committee meetings.</b> <b>PRO data should be treated with the same importance as other data in monitoring clinical site performance</b>
				<b>Monitoring at site level</b> <b>Collect reasons for missing PRO data/about non-responders</b> Introduce a fixed daily work routine where nurses checked notification lists Prepare for upcoming assessments (e.g. have questionnaires ready) Document procedure of PRO data collection at each centre, including names and contacts of those involved Provide PRO assessment schedule for each patient to attending physician and keep in patient file
<b>Reminder</b> <b>Send participants PRO assessment reminders</b> After no response, including an automated reminder, a human should contact the participant <b>Send site staff reminders for upcoming/overdue PRO assessments</b>				
<b>Resources</b> Staff and patients should be provided with the necessary resources for optimal data collection Integrate PROs into clinical systems to allow for efficient use by clinicians Clinical resourcing to deal with issues reactively outside of clinical appointments				

Abbreviations: EORTC, European Organisation for Research and Treatment of Cancer; ePRO, electronic patient-reported outcome; ePROM, electronic patient-reported outcome measure; MOA, mode of assessment; nr, number; SPIRIT, Standard Protocol Items: Recommendations for Interventional Trials; PROM, patient-reported outcome measure; PRO, patient-reported outcome;

\*Bold recommendations indicate that the recommendation was found in 2 papers. Bold and italicized recommendations indicate that the recommendation was found in 3 or more papers.

sending reminders to patients and providing them with education improves completion rates, but may also increase patient burden [11,13,19,20,22,23]. Patient burden refers to how challenging, time-consuming, and emotionally stressful patients perceive their study participation [28]. Distress has been reported among advanced cancer patients receiving reminders as this reminds them of their poor health and HRQoL [16]. Therefore, sending reminders for the completion of PROMs may not prove beneficial for all patient populations.

Consequently, it is crucial to carefully assess the feasibility and practicality of implementing such a comprehensive set of recommendations, taking into consideration the potential burden on patients, staff and sites involved in the clinical trial process. Careful evaluation of the potential benefits and disadvantages of each recommendation before implementation is essential. Analyses of PRO completion rates of EORTC

trials between 1996 and 2011 showed different completion rates (23 – 92 %) depending on the trial and population characteristics [38]. Variability in PRO completion rates have also been previously reported. Moreover, despite the availability of numerous recommendations, PRO completion rates tend to decrease over time. This raises questions about the feasibility and effectiveness of these recommendations in real-world settings. Therefore, the next phase of this research will involve conducting interviews with clinical trialists and other stakeholders engaged in PROM design study design and collection. These interviews will provide insight into the applicability and usefulness of the identified recommendations. The outcomes of this scoping review combined with the analyses of EORTC trials and the forthcoming interviews, will serve as a foundational resource for developing guidance to improving PRO completion rates in cancer clinical trials.

## 4.2. Limitations

This review has limitations. Only papers published in bibliographic databases or documents produced by leading cancer and public health organisations were included. This criterion was applied to guarantee the validity and methodological quality of the included literature. Furthermore, only literature published since January 2012 was included to reflect on current practices. Another limitation is that non-English papers were excluded. By doing so, we might have overlooked relevant national guidelines or regulatory aspects.

## 5. Conclusion

Missing PRO data in cancer clinical trials remains a challenging issue, influencing the quality of the derived results [39]. This may result in underutilization of PRO data, wasting patient time and resources or leading to erroneous conclusions regarding the patients' perspectives and the trial outcomes. This scoping review includes a plethora of recommendations for improving PROMs completion rates in cancer clinical trials. However, the practicality and effectiveness of these recommendations remain unclear. More research is needed on the feasibility and prioritization of these recommendations, as well as providing guidance on improving PRO completion rates in cancer trials.

## CRedit authorship contribution statement

**Roger Wilson:** Writing – review & editing. **John K. Ramage:** Writing – review & editing. **Vesna Bjelic-Radiscic:** Writing – review & editing. **Katarzyna Wac:** Data curation, Formal analysis, Writing – review & editing. **Susanne Singer:** Writing – review & editing. **Jolie Ringash:** Writing – review & editing. **Olga Husson:** Writing – review & editing. **Hans-Henning Flechtner:** Writing – review & editing. **Abigirl Machingura:** Conceptualization, Data curation, Formal analysis, Writing – review & editing. **Lotte Van der Weijst:** Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing. **Michael Koller:** Writing – review & editing. **Galina Velikova:** Writing – review & editing. **Jens Lehmann:** Writing – review & editing. **Renée Bultijnc:** Data curation, Formal analysis, Writing – review & editing. **Heike Schmidt:** Writing – review & editing. **Madeline Pe:** Conceptualization, Funding acquisition, Supervision, Writing – review & editing. **Katherine J. Taylor:** Writing – review & editing. **Winette T.A. van der Graaf:** Writing – review & editing. **Kathy Oliver:** Writing – review & editing. **Lúcia P.C. Senna:** Data curation, Formal analysis, Writing – review & editing. **Emma Lidington:** Data curation, Formal analysis, Writing – review & editing. **Lisa Wintner:** Data curation, Formal analysis, Writing – review & editing. **Ahu Alanya:** Data curation, Formal analysis, Writing – review & editing.

## Funding

European Organisation for Research and Treatment of Cancer Quality of Life Group [Grant number: 015/2021].

## Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.ejca.2024.114313](https://doi.org/10.1016/j.ejca.2024.114313).

## References

- [1] Coens C, Pe M, Dueck AC, Sloan J, Basch E, Calvert M, et al. International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. *Lancet Oncol* 2020;21:e83–96. [https://doi.org/10.1016/S1470-2045\(19\)30790-9](https://doi.org/10.1016/S1470-2045(19)30790-9).
- [2] Churrua K, Pomare C, Ellis LA, Long JC, Henderson SB, Murphy LED, et al. Patient-reported outcome measures (PROMs): a review of generic and condition-specific measures and a discussion of trends and issues. *Health Expect* 2021;24: 1015–24. <https://doi.org/10.1111/hex.13254>.
- [3] Calvert M, Brundage M, Jacobsen PB, Schünemann HJ, Efficace F. The CONSORT patient-reported outcome (PRO) extension: implications for clinical trials and practice. *Health Qual Life Outcomes* 2013;11:1–7. <https://doi.org/10.1186/1477-7525-11-184>.
- [4] Yu H, Yu Q, Nie Y, Xu W, Pu Y, Dai W, et al. Data quality of longitudinally collected patient-reported outcomes after thoracic surgery: comparison of paper- and web-based assessments. *J Med Internet Res* 2021;23:e28915. <https://doi.org/10.2196/28915>.
- [5] Bell ML, Fiero M, Horton NJ, Hsu CH. Handling missing data in RCTs: a review of the top medical journals. *BMC Med Res Method* 2014;14:1–8. <https://doi.org/10.1186/1471-2288-14-118>.
- [6] Mercieca-Bebber R, Palmer MJ, Brundage M, Calvert M, Stockler MR, King MT. Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review. *BMJ Open* 2016;6. <https://doi.org/10.1136/bmjopen-2015-010938>.
- [7] Bernhard J, Cella DF, Coates AS, Fallowfield L, Ganz PA, Moinpour CM, et al. Missing quality of life data in cancer clinical trials: serious problems and challenges. *Stat Med* 1998;17:517–32. [https://doi.org/10.1002/\(sici\)1097-0258\(19980315/15\)17:5<517::aid-sim799>3.0.co;2-s](https://doi.org/10.1002/(sici)1097-0258(19980315/15)17:5<517::aid-sim799>3.0.co;2-s).
- [8] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ (Online)* 2009; 339:332–6. <https://doi.org/10.1136/bmj.b2535>.
- [9] Calvert M, King M, Mercieca-Bebber R, Aiyegbusi O, Kyte D, Slade A, et al. SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. *BMJ Open* 2021;11. <https://doi.org/10.1136/bmjopen-2020-045105>.
- [10] Appleyard SE, Larkin MJW, Stewart EM, Minton O, Gilbert DC. Digital medicine in men with advanced prostate cancer – a feasibility study of electronic patient-reported outcomes in patients on systemic treatment. *Clin Oncol* 2021;33:751–60. <https://doi.org/10.1016/j.clon.2021.04.008>.
- [11] Pugh SL, Rodgers JP, Moughan J, Bonanni R, Boparai J, Chen RC, et al. Do reminder emails and past due notifications improve patient completion and institutional data submission for patient-reported outcome measures? *Qual Life Res* 2021;30:81–9. <https://doi.org/10.1007/s11136-020-02613-3> LK - <http://sfxcit.ugent.be/ugent?sid=EMBASE&issn=15732649&id=doi:10.1007%2Fs11136-020-02613-3&title=Do+reminder+emails+and+past+due+notifications+improve+patient+completion+and+institutional+data+submission+for+patient-reported+outcome+measures%3F&title=Qual.+Life+Res.&title=Quality+of+Life+Research&volume=30&issue=1&spage=81&epage=89&aulast=Pugh&aufirst=Stephanie+L.&auinit=S.L.&aufull=Pugh+S.L.&coden=QLREE&isbn=&pages=81-89&date=2021&auinit1=S&auinitm=L>.
- [12] Zivanovic O, Chen LY, Vickers A, Straubhar A, Baser R, Veith M, et al. Electronic patient-reported symptom monitoring in patients recovering from ambulatory minimally invasive gynecologic surgery: a prospective pilot study. *Gynecol Oncol* 2020;159:187–94.
- [13] Atherton PJ, Burger KN, Pederson LD, Kaggal S, Clinic M. Patient reported outcomes questionnaire compliance in cancer cooperative group trials (Alliance N0992). *Clin Trial: J Soc Clin Trial* 2016;13:612–20. <https://doi.org/10.1177/1740774516655101.Patient>.
- [14] King-Kallimianis BL, Lederer NM, Kim J, Nair A, Horodniceanu E, Bhatnagar V, et al. Patient-reported outcomes after treatment discontinuation: commercial clinical trial data from four cancer types. *Value Health* 2021;24:1302–7. <https://doi.org/10.1016/j.jval.2021.04.1279>.
- [15] Lidington E, Hogan H, Gandolfi A, Lawrence J, Younger E, Cho H, et al. Assessing the collection and reporting of patient-reported outcome data in interventional cancer trials: a single institution, retrospective systematic evaluation. *J Patient Rep Outcomes* 2022;6. <https://doi.org/10.1186/s41687-022-00529-9>.
- [16] Tran C, Dicker A, Leiby B, Gressen E, Williams N, Jim H. Utilizing digital health to collect electronic patient-reported outcomes in prostate cancer: Single-arm pilot trial. *J Med Internet Res* 2020;22. <https://doi.org/10.2196/12689>.
- [17] Kennedy F, Absolom K, Clayton B, Rogers Z, Gordon K, O'Connell Francischetto E, et al. Electronic patient reporting of adverse events and quality of life: a prospective feasibility study in general oncology. *JCO Oncol Pract* 2021;17: e386–96. <https://doi.org/10.1200/OP.20.00118>.
- [18] Movsas B, Hunt D, Watkins-Bruner D, Lee WR, Tharpe H, Goldstein D, et al. Can electronic web-based technology improve quality of life data collection? Analysis of radiation therapy oncology group 0828. *Pract Radiat Oncol* 2014;4:187–91. <https://doi.org/10.1016/j.prro.2013.07.014>.
- [19] European Medicines Agency. EMEA Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man 2014;44:1–18.
- [20] Teixeira MM, Borges FC, Ferreira PS, Rocha J, Sepodes B, Torre C. A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020. *Front Med (Lausanne)* 2022;9. <https://doi.org/10.3389/fmed.2022.968272>.
- [21] European Organisation for Research and Treatment of Cancer Quality of Life Group. Guidelines for assessing Quality of Life in EORTC clinical trials; 2002.



- [22] Romano C, Harris N, Gnanasakthy A, D'Alessio D, Chandiwana D. Patient experiences with patient-reported outcome measures in metastatic breast cancer trials: qualitative interviews. *J Patient Rep Outcomes* 2022;6. <https://doi.org/10.1186/s41687-022-00460-z>.
- [23] Basch E. High Compliance Rates With Patient-Reported Outcomes in Oncology Trials Submitted to the US Food and Drug Administration; 2019;111:2018–2020. <https://doi.org/10.1093/jnci/djy183>.
- [24] Flannery MA, Mohile S, Culakova E, Norton S, Kamen C, Dionne-Odom JN, et al. Completion of patient-reported outcome questionnaires among older adults with advanced cancer. *J Pain Symptom Manag* 2022;63:301–10. <https://doi.org/10.1016/j.jpainsymman.2021.07.032>.
- [25] Hoque DME, Earnest A, Ruseckaite R, Lorgelly P, Sampurno F, Evans M, et al. A randomised controlled trial comparing completeness of responses of three methods of collecting patient-reported outcome measures in men diagnosed with prostate cancer. *Qual Life Res* 2019;28:687–94. <https://doi.org/10.1007/s11136-018-2061-7>.
- [26] Giordano FA, Welzel G, Siefert V, Jahnke L, Ganslandt T, Wenz F, et al. Digital follow-up and the perspective of patient-centered care in oncology: what's the problem? *Oncol (Switz)* 2020;98:379–85. <https://doi.org/10.1159/000495294>.
- [27] Friis RB, Hjollund NH, Hjollund NH, Mejdahl CT, Pappot H, Skuladottir H. Electronic symptom monitoring in patients with metastatic lung cancer: a feasibility study. *BMJ Open* 2020;10:1–9. <https://doi.org/10.1136/bmjopen-2019-035673>.
- [28] Aiyegbusi OL, Roydhouse J, Rivera SC, Kamudoni P, Schache P, Wilson R, et al. Key considerations to reduce or address respondent burden in patient-reported outcome (PRO) data collection. *Nat Commun* 2022;13:6026. <https://doi.org/10.1038/s41467-022-33826-4>.
- [29] Mowlem FD, Elash CA, Dumais KM, Haenel E, O'Donohoe P, Olt J, et al. Best practices for the electronic implementation and migration of patient-reported outcome measures. *Value Health* 2024;27:79–94. <https://doi.org/10.1016/j.jval.2023.10.007>.
- [30] Staniszewska S, Haywood K.L., Brett J., Tutton L. Patient and Public Involvement in Patient-Reported Outcome Measures Evolution Not Revolution. n.d.
- [31] Addario B, Geissler J, Horn MK, Krebs LU, Maskens D, Oliver K, et al. Including the patient voice in the development and implementation of patient-reported outcomes in cancer clinical trials. *Health Expect* 2020;23:41–51. <https://doi.org/10.1111/hex.12997>.
- [32] Price A, Albarqouni L, Kirkpatrick J, Clarke M, Liew SM, Roberts N, et al. Patient and public involvement in the design of clinical trials: an overview of systematic reviews. *J Eval Clin Pract* 2018;24:240–53. <https://doi.org/10.1111/jep.12805>.
- [33] de Wit M, Cooper C, Reginster JY. Practical guidance for patient-centred health research. *Lancet* 2019;393:1095–6. [https://doi.org/10.1016/S0140-6736\(19\)30034-0](https://doi.org/10.1016/S0140-6736(19)30034-0).
- [34] Roberts NA, Alexander K, Wylid D, Janda M. What is needed by staff to implement PROMs into routine oncology care? A qualitative study with the multi-disciplinary team. *Eur J Cancer Care (Engl)* 2019;28. <https://doi.org/10.1111/ecc.13167>.
- [35] Boyce MB, Browne JP, Greenhalgh J, Boyce M. The experiences of professionals with using information from patient-reported outcome measures to improve the quality of healthcare: a systematic review of qualitative research; 2014. <https://doi.org/10.1136/bmjqs>.
- [36] Schamber EM, Takemoto SK, Chenok KE, Bozic KJ. Barriers to completion of patient reported outcome measures. *J Arthroplast* 2013;28:1449–53. <https://doi.org/10.1016/j.arth.2013.06.025>.
- [37] European Commission Directorate-General for Education and Culture. The Survey of Adult Skills (PIAAC): Implications for education and training policies in Europe 2013:1–27.
- [38] Machingura A, Weijst L van de, Lim L, Coens C, Ghislain I, Alanya A, et al. A review of Health-Related Quality of Life (HRQoL) completion rates and reason for low completion in closed EORTC trials. *International Society for Quality of Life Research Abstract*; 2023.
- [39] Bell ML, Fairclough DL. Practical and statistical issues in missing data for longitudinal patient-reported outcomes. *Statistical. Methods Med Res* 2014;23:440–59. <https://doi.org/10.1177/0962280213476378>.